21-Hydroxylase Antibody
Steroid 21-hydroxylase (55 kDa) is a key enzyme involved in steroid biosynthesis, which converts 17-OH-progesterone and progesterone into 11-deoxycorticosterone. Autoantibody against 21-hydroxylase is considered an important marker of autoimmune adrenal disease. Autoimmune destruction of the adrenal cortex is the most common cause of idiopathic Addison’s disease and 70-90% of these patients are associated with increased serum concentration of 21-hydroxylase antibody (21-OH Ab).
Autoimmune Addison’s disease can occur as a single disorder or as part of autoimmune polyendocrine syndrome type 1 (APS I) and type II (APS II). APS I is characteristically comprised of Addison’s disease, hypoparathyroidism, and mucocutaneous candidiasis. Several other endocrine and non-endocrine manifestations in APS I include diabetes mellitus, hypergonadotropic hypogonadism, autoimmune hepatitis, malabsorption, enamel dysplasia, and keratopathy. APS II is defined as a combination of Addison’s disease with autoimmune thyroid disease and/or type 1 diabetes mellitus.
Healthy individuals rarely have autoantibodies against the endocrine glands. The detection of elevated concentration of 21-OH Ab indicates the presence of adrenal autoantibodies, which is consistent with Addison’s disease. These antibodies may present much earlier than the endocrine function impairment and clinical symptom onset. Therefore, 21-OH Ab can also be used to predict the future risk of development of adrenal destruction in an individual with APS.
- As an aid in diagnosis of primary adrenal insufficiency (Addison’s disease)
- As an aid in diagnosis of autoimmune polyglandular syndrome type 1 or 2
- Therapy and disease management
Increased in:
- Addison’s disease
- Autoimmune polyglandular syndrome (APS), Type 1 or 2
- Hypoparathyroidism
- Goiterous autoimmune thyroiditis
- Atrophic autoimmune thyroiditis
- Hyperthyroidism
- Type I diabetes mellitus
- Pernicious anemia
< 1.0 U/L
Serum (SST tubes)
Stability
- Ambient: unacceptable
- Refrigerated: 7 days
- Frozen: 6 months
- J Intern Med. 2014;275:104-15. [PMID: 24330030]
- J Clin Endocrinol Metab. 2006;91:1637-45. [PMID: 16522688]
- Endocr Rev. 2002;23:327-64. [PMID: 12050123]
- Eur J Endocrinol. 2000;142:187-94. [PMID: 10664529]
- J Clin Endocrinol Metab. 1998;83:3507-11. [PMID: 9768655]
- J Clin Endocrinol Metab. 1997;82:1440-6. [PMID: 9141530]
- J Clin Endocrinol Metab. 1996;81:1871-6. [PMID: 8626850]
- Clin Exp Immunol. 1967;2:19-30. [PMID: 6030795]